About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own businessabc Wiki

Boost credibility, visibility, and discoverability

Learn More
Last Updated: 2026
Cipla image

Cipla

Rank#1816
Market Cap12.09B
CountryIndia
Summary
History
Mission
Vision
References
Summaryarrow
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
Historyarrow

In 1935, Cipla was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in Mumbai.

In July 1984, the name of the company was changed to 'Cipla Limited'.In 1985, the US FDA approved the company's bulk drug against HIV and other drugs to treat poor people in the developing world.

Led by the founder's son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world.

In 1995, Cipla launched Deferiprone, the world's first oral iron chelator. In 2001, Cipla offered antiretrovirals for HIV treatment at a fractional cost .In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited. At the time of the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third biggest pharmaceutical company. The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company, and in 2008 it changed its name to Cipla-Medpro.In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.In 2019 Cipla entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa.

Missionarrow
Ciplas mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients.
Visionarrow
Cipla’s vision is to be a global leader in select specialty therapeutics, providing access to quality medicines for Australian consumers at affordable prices.
Referencesarrow

https://en.wikipedia.org/wiki/Cipla

https://in.investing.com/equities/cipla

https://finance.yahoo.com/quote/CIPLA.NS/profile?p=CIPLA.NS

https://www.comparably.com/companies/cipla/mission

https://www.crunchbase.com/organization/cipla

https://companiesmarketcap.com/

https://www.cipla.com

Share

Leadership team
M
Mr. Umang Vohra (MD, Global CEO & Exec. Director)
M
Ms. Samina Hamied (Exec. Vice-Chairperson)
D
Dr. Raju Sunil Mistry M.A., Ph.D. (Pres & Global Chief People Officer)
Products / Services
Biotechnology, Health Care, Manufacturing, Medical, Pharmaceutical
Number of Employees
20,000 - 50,000
Address
Mumbai, Maharashtra, India
Established
1935-01-01
Net Income
S_100M_500M
Revenue
$1B+
Traded as
CIPLA.NS
Website
https://www.cipla.com
Social Media
linkedinfacebookx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo